Zai Lab Placement: Beware of Performance of Last Deal Despite Decent Fundamentals
Zai Lab announced an offering of 50 million ADS to raise up to USD 150 million. We have covered the company's IPO in 2017. In this insight, we will...
549 Views
HLX02: Innovation Could Overtake
The oncology treatment landscape in China is evolving rapidly as the government has prioritized access to innovative drugs to meet this significant...
479 Views
Ascletis Pharma (歌礼制药) IPO: Valuation Not Justified by Ganovo and Ravidasvir NPV (Part 3)
Corrigenda: There is an error in this insight, please note the correction. Correction: The drug name Conbercept has been misspelt as...
850 Views
Ascletis Pharma (歌礼制药) IPO: Three Valuation Risk Factors (Part 2)
In our last Insight covering Ascletis Pharma (Ascletis Pharma (歌礼制药) IPO: Emerging Player in the Crowded HCV Drug Market ), we discuss the...
535 Views
Smartkarma: ECM Coverage Weekly Update (23 September 2017)
The Smartkarma ECM Team puts out a weekly update on the deals we have covered recently, along with updates for upcoming IPOs. This week we see...
196 Views